An HBR Executive Live conversation with Michael Fiddelke. by HBR Editors
November 11, 2025
In 2003, Michael Fiddelke joined Target as an intern on the finance team, and this coming February, he will take over as CEO. Over two decades, he has helped steer the company through economic headwinds, shifting consumer expectations, and a rapidly evolving retail landscape, all while trying to preserve the brand’s distinct identity. His vantage point on the intersection of finance, strategy, and operations gives him a rare perspective on how large organizations can adapt and evolve.
Seth Ketron, associate professor of marketing at the University of St. Thomas Opus College of Business, spoke with KSTP about how shoppers and retailers are approaching the holiday season amid economic uncertainty. He discussed how consumers can plan strategically for the best deals, how artificial intelligence is changing shopping habits, and why this year’s market conditions are prompting more thoughtful spending.
There was a time when most cutting-edge industrial research was conducted at massive corporate R&D organizations like DuPont Central Research and Development and General Electric’s campus in Schenectady, New York. Such institutions went the way of the battleship and horse-drawn buggy. Big companies still do research, of course, but it tends to be honed more to meeting the immediate needs of their businesses than to making big breakthroughs.
Start-ups now take on many of the risks in innovation, and in C&EN’s latest 10 Start-Ups to Watch, which were revealed on Monday, we profile noteworthy new companies that may come up with the next big thing. The firms aim to make textile dyeing more sustainable, carbon capture more affordable, and cancer drugs more precise. Enjoy reading!
Questions? Comments? Tips? Let us know. Email Alex Tullo, C&EN’s senior correspondent for business, at a_tullo@acs.org.
Top stories from C&EN
Gloved hands pipette some liquid in a laboratory.
New biotechs are having a difficult time raising cash.
Credit:
Lander Loeckx/Alamy
Despite a spate of recent deals, biotechnology financing is still slow as big pharma and venture capital firms continue to take a cautious approach to dealmaking.
Arena BioWorks, cofounded in 2024 by Stuart Schreiber, also one of the founders of the interdisciplinary Broad Institute of MIT and Harvard, has shut down amid a poor financing and uncertain policy environment.
Consumer products companies aren’t meeting the plastics sustainability commitments they made years ago, and plastics recyclers are suffering.
Business in brief
Ineos negotiates exit for China petrochemical venture
Ineos is in negotiations with its partner, the Chinese state-owned oil and chemical company Sinopec, to exit their petrochemical joint venture in Tianjin, China. Ineos bought into the partnership in 2023, when the complex was already under construction. According to Sinopec, it started up in 2024. The facility has a 1.2 million-metric-ton-per-year ethylene cracker and downstream polyethylene and other derivatives units. In a financial report, Ineos said that move was “due to continuing weak market conditions in China.” The joint venture, as well as another Ineos partnership with Sinopec, Shanghai Secco Petrochemical, lost money in the third quarter. When Ineos bought into Secco in 2022 it was supposed to be the start of a broader collaboration between the two firms.
—Alex Tullo
Oman explores green methanol hub
People in suits sign an agreement on a wooden conference table with an imposing bookcase in the background.
Omani government and private sector officials sign an agreement for a new methanol complex.
Credit:
Foreign Ministry of Oman
The government of Oman is working with a consortium of Spanish companies to develop a facility in the country to produce e-methanol—methanol made from renewable electricity and captured CO2—and use it to fuel maritime vessels. Oman is located on the Arabian Sea near major shipping routes. Officials from Oman’s transportation ministry signed a set of agreements with Acciona & Nordex Green Hydrogen, the e-fuels developer HIF Global, and the regional investor Al Meera. The partners say the deals set up legal and business frameworks for the partners to select sites, share technology information, and start regulatory work to support a project in Oman’s Dhofar region.
—Craig Bettenhausen
Vianode to build graphite plant in Ontario
The battery anode materials maker Vianode has announced plans for a multibillion-dollar synthetic graphite plant in Ontario. The firm says the project will start with an initial investment of $1.425 billion and expand from there, aiming at a final capacity of 150,000 metric tons per year. That first phase will employ 300 people when it starts production as early as 2028, Vianode says, and the fully realized facility will have 1,000 jobs. The firm uses petroleum coke, a by-product of oil refining, as its raw material. The company opened its first commercial facility in Norway in 2024. Vianode says that in addition to electric vehicles it will target applications in semiconductors, nuclear reactors, and steel production.
—Craig Bettenhausen
Air Products looks to turn Louisiana blue hydrogen gray
The industrial gas firm Air Products and Chemicals is negotiating deals that would convert a planned low-carbon hydrogen project in Louisiana into a conventional hydrogen production site, CEO Eduardo Menezes told investors during the firm’s fourth-quarter earnings call. The original plan was to make hydrogen from natural gas while capturing the resulting CO2 emissions for geological sequestration. Menezes said Air Products is divesting the CO2 capture and sequestration part of that, including the connected underground pore space it was developing. To the extent the firm does find customers willing to pay a premium to sign long-term contracts for decarbonized hydrogen and ammonia, it will contract with the buyer to provide carbon capture as a service, he said. Menezes also left the door open to canceling the project entirely and separately selling off the sequestration pore space.
—Craig Bettenhausen
BASF starts up units at big China complex
A sprawling new petrochemical complex on a human-made peninsula.
BASF’s integrated site in Zhanjiang, China.
Credit:
BASF
BASF has started manufacture of the first products at its new Verbund integrated chemical complex in Zhanjiang, China. The company, which owns and controls the site, started construction in 2020; BASF’s board approved the main elements of the complex, including an ethylene steam cracker, in 2022. BASF says that at a total cost of $10 billion, the project’s construction is coming in under budget.
—Alex Tullo
Quote of the week
“Science has always been a human endeavor. The way we reason about the world and the way a scientific superintelligence would reason about the world may not be exactly the same, right? It might be that the way our own cognition has shaped how we do science is not the only way to do science.”
LanzaTech gets cash to turn greenhouse gases into ethanol
The biobased chemical maker LanzaTech says the European Union’s Innovation Fund has awarded it a €40 million ($46.2 million) grant to help it build a plant in Norway that will turn smelter furnace gases into ethanol. The US firm says the project will produce up to 23,500 metric tons of the alcohol per year from carbon monoxide–rich gas generated in Eramet’s manganese smelter in Porsgrunn, Norway. Carbon dioxide created in the process will be liquefied and stored in geological formations under the North Sea. LanzaTech operates six similar facilities in China and Belgium, but it has long struggled to become profitable. An investor in LanzaTech, Carbon Direct Capital Management, offered to buy it at a discount in April, saying the sale might be the only thing that keeps the company from going bankrupt.
—Michael McCoy
Element Solutions to acquire electronic materials maker EFC
In its second deal announcement in as many weeks, Element Solutions has agreed to buy EFC Gases & Advanced Materials for about $360 million. EFC is a supplier of high-purity specialty gases for semiconductor and other applications that, according to Element, has grown at a compound annual rate of more than 15% since 2009. In July 2024, EFC announced plans to build a $210 million semiconductor chemical facility in McGregor, Texas. The purchase announcement follows an Element agreement to buy Celanese’s Micromax unit, a maker of inks and pastes used in electronics, for about $500 million. Element said at the time that the purchase would increase its sales to the electronics industry to about $2 billion per year.
—Michael McCoy
Evotec to sell French biologics plant to Sandoz for $350 million
The generic drug maker Sandoz has agreed to purchase a manufacturing facility from the German drug discovery firm Evotec Biologics for $350 million. The site, in Toulouse, France, has in-built technology for continuous manufacturing of biologics. The two companies partnered for the first time in 2023; that move allowed Sandoz to access Evotec’s artificial intelligence–driven, continuous manufacturing technology to develop biologics. It was around that time that Sandoz separated from Novartis to become an independent company. Meanwhile, the new deal could yield more money for Evotec, with royalties of over $650 million on up to 10 biosimilar molecules developed by Sandoz.
—Aayushi Pratap
Novo Nordisk loses to Pfizer in bid for Metsera
A bidding war for the weight-loss drug developer Metsera erupted in late October when Novo Nordisk made an unsolicited offer for the company—despite it already having signed a merger agreement with Pfizer. In response, Pfizer raised its bid and filed a suit accusing Novo and certain Metsera shareholders of anticompetitive conduct. Novo returned with a higher proposal, but Metsera ultimately chose Pfizer’s further revised offer, valued at up to $10 billion, saying that it carried lower regulatory and antitrust risk. Novo says it will not be making an increased offer. Pfizer has since initiated a second legal action claiming that Novo had no real intent to buy the company.
—Elizabeth Walsh
Azalea Therapeutics launches with $82 million for gene therapy
Azalea Therapeutics has launched with $82 million in series A funding and technology that it says can make in vivo precision genome editing possible. The start-up evolved out of a collaboration between Nobel laureate Jennifer Doudna and University of California, San Francisco, professor Justin Eyquem. The firm says it can deliver CRISPR-Cas9 gene editing machinery directly into human T cells using a T-cell-tropic adeno-associated virus vector, thus removing the need to manufacture edited T cells for chimeric antigen receptor T-cell therapy in the lab.
—Max Barnhart
What we’re reading
Fierce Biotech remembers all the biotechs lost in 2025 in its latest Biotech Graveyard: Fierce Biotech
Doctors probe a link between chemicals and Parkinson’s disease: Wall Street Journal
How The Line, the Saudi dream of a 100 km super city, is unraveling: Financial Times
The Trump administration has launched its most direct attempt yet to shut down the top US consumer watchdog, arguing the current funding mechanism behind the Consumer Financial Protection Bureau (CFPB) is unlawful.
Attorneys for the administration claimed in a court filing that the agency “anticipates exhausting its currently available funds in early 2026”, setting the stage for it to be dismantled.
The CFPB is legally barred from seeking additional funds from the Federal Reserve, its typical source of funding, the attorneys suggested.
Donald Trump’s officials have tried persistently to close the agency, attempting to fire the vast majority of its workforce. These efforts sparked months of legal wrangling.
The CFPB has returned more than $21bn to US consumers since it was set up, in the wake of the financial crisis, to shore up oversight of consumer financial firms.
The justice department’s office of legal counsel issued an opinion claiming the CFPB cannot draw money from the Fed currently, claiming the “combined earnings of the Federal Reserve System” refers to profits of the Fed, which has operated at a loss since 2022.
Several federal judges have previously rejected that argument used by companies attempting to dismiss lawsuits brought by the agency, reported Politico.
Russell Vought, the White House office of management and budget director, said in October that he plans to shut down the agency, and that this would take up to three months.
The claim was criticized by Democrats, given previous contrary statements from the administration, and court decisions blocking the agency from being shut down.
“These comments are particularly concerning given that a federal court has specifically blocked you from illegally shutting down the agency,” wrote Senate banking committee Democrats in a letter to Vought. “Your continued attempts to shutter the CFPB are illegal, and American families stand to pay the price.”
Vought has already suspended most of the agency’s work, as the full DC circuit court of appeals is deciding whether to take the case as a lower court order blocked the firings of about 90% of the agency’s staff.
The CFPB did not immediately respond to a request for comment.
I covered Palantir exactly three weeks ago here on CNBC Pro before Q3 earnings, looking for a breakout from $190. We did see the breakout through $190 to a high of $207.50 right before earnings. Immediately after earnings, despite a historic quarter, the stock got “Burry’ed” below $170 last week and is now back to $190. In that time, Michael Burry — famed short seller from the movie “The Big Short” — and Alex Karp have exchanged barbs. Here’s the chronology of events. Oct. 30 – Burry returns to X warning of an AI bubble. Nov. 3 – PLTR reports record quarter, holds 5 p.m. conference call, highlights rule of 40 (will expand below). Nov. 3 – Burry’s Scion Asset Management files 13F with short positions via long puts in NVDA and PLTR. Nov. 4 – Alex Karp responds on CNBC calling Burry ” bats— crazy ” Nov. 5-6 – The Karp / Burry debate and $1 billion bet against AI spread rapidly Nov. 9 – Burry claims the interpretation of the 13F by Karp and others lacks proper information for valid conclusions: “Can’t crack a simple 13F.” Nov. 10 – Burry disputes hyperscaler capex hardware depreciation schedule claims earnings overstated What can we make of all of this? You’ll notice the Nasdaq-100 topping in late October following Burry’s initial X post (and first X post in two years) and Scion’s 13F report released showing short positions in NVDA and PLTR, but Palantir stock rallying sharply into the Q3 earnings print 2 days later. The Q3 earnings report was nothing short of stellar, but the stock reacted sharply on the downside amidst the scuttlebutt with Burry catching down to the Nasdaq-100. Let’s review the Q3 earnings to get some context: Adjusted EPS came in at 21 cents compared to 10 cents in the same quarter last year for 110% growth. Expectations were for 17 cents per share so EPS beat street expectations by 25.46%. EBITDA margins this quarter grew to 51.4% vs expectations of 45.8%, and 39.09% seen in the same quarter last year. A particular metric investors were watching was the total revenue figure ($1.18 billion – up 63% year-over-year) broken down by commercial and government contracts. If there was too much contribution by government contracts the view would have been that may be unsustainable and the stock would react negatively. However, U.S. commercial sales grew by 121% year over year to $397 million, which was well ahead of what the street was expecting. The contract backlog was massive indicating strong future demand. As a result they raised full-year 2025 guidance to $4.396-$4.40 billions and US commercial expected to top $1.433 billion. The shift towards commercial contracts helps drive forward the narrative that Palantir is becoming less of a government/defense contractor and more of an enterprise AI software company. During the conference call, CEO Alex Karp stressed the “Rule of 40” which is a popular metric used by Saas (Software-as-a-Service) business to evaluate companies by a single metric. (Rule of 40 = revenue growth rate + Operating margin). If the sum is higher than 40, the company is considered to be performing well. With Palantir’s revenue growth rate at 63 and operating margin at 51, Alex Karp added the two figures together to arrive at a reading of 114. This signifies to investors that Palantir may no longer buy a highly valued pie in the sky growth story, but a company that’s evolving into a profit generation machine. For comparison, here are four other Saas companies with their Rule of 40 reading. Snowflake (SNOW) : 47% Datadog (DDOG) : 56.7% ServiceNow (NOW) : 53% Adobe (ADBE) : 50.6% With these kind of fundamental growth rates combined with this scale and market cap, the liquidity in this stock is deep and attracting large institutional interest. The weekly chart shows a nice pullback into a uptrend line from mid-24 as well as the 20-week moving average. Turning to the daily chart you can see the whirlwind roundtrip the stock has been on amidst the back and forth between Karp and Burry. PLTR “Burry’ed” the stoops below the 20-day MA, 50-day MA, and even that weekly uptrend line before gapping back above the $190 level on above average (50-day average) volume. We’re still holding an 8.5% allocation in our fast money portfolio and a 2% allocation in our flagship growth model at Inside Edge. If the dust clears and we see a clean breakout into the $200’s and above we’re going to increase position size in both portfolios. We’ll have to see if Burry was a one-hit wonder with his short in real estate, or if he can do it again with his (confusing) call of being bearish in the AI revolution. -Todd Gordon, Founder of Inside Edge Capital, LLC We offer active stock alerts, portfolio management, as well as regular market updates like the idea presented above here . DISCLOSURES: Gordon owns PLTR personally and in his wealth management company Inside Edge Capital All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
China’s cybersecurity agency accused the American government of orchestrating the theft about $13 billion worth of Bitcoin, representing China’s most recent attempt to attribute major cyberattacks to the US.
The theft of the 127,272 Bitcoin tokens from the LuBian Bitcoin mining pool that took place in December 2020 marks as one of the largest crypto heists in history. The hack, according to the Chinese National Computer Virus Emergency Response Center, is likely a “state-level hacker operation” led by US, citing the quiet and delayed movement of the stolen Bitcoin fits a government-level action rather than a typical criminal behavior.